Covaxin, an indigenously developed vaccine by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) generates antibodies that effectively neutralise both Alpha and Delta variants of coronavirus, the National Institute of Health (NIH) in the United States said in a statement. It asserted that the results from two studies of blood serum from people who had received COVAXIN suggest that the vaccine generates antibodies that effectively neutralize the B.1.1.7 (Alpha) and B.1.617 (Delta) variants of SARS-CoV-2.

Covaxin, an indigenously developed vaccine by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) generates antibodies that effectively neutralise both Alpha and Delta variants of coronavirus, the National Institute of Health (NIH) in the United States said in a statement. It asserted that the results from two studies of blood serum from people who had received COVAXIN suggest that the vaccine generates antibodies that effectively neutralize the B.1.1.7 (Alpha) and B.1.617 (Delta) variants of SARS-CoV-2.